Search results for "mildronate"

showing 6 items of 6 documents

Glikozes transportieru un slāpekļa oksīda produkcijas izmaiņas cukura diabēta komplikāciju patoģenēzē un to farmakoloģiskās korekcijas iespējas

2014

Elektroniskā versija nesatur pielikumus

14-dihidropiridīnimildronātsmildronateMedical biochemistrydiabetic complicationsMedicīna un farmācijaMedicīniskā bioķīmijacukura diabēta komplikācijasVeselības aprūpeMedicīna14-dihydropyridines
researchProduct

Search for Stroke-Protecting Agents in Endothelin-1-Induced Ischemic Stroke Model in Rats

2012

Background and Objective. Ischemic stroke may initiate a reperfusion injury leading to brain damage cascades where inflammatory mechanisms play a major role. Therefore, the necessity for the novel stroke-protecting agents whose the mechanism of action is focused on their anti-inflammatory potency is still on the agenda for drug designers. Our previous studies demonstrated that cerebrocrast (a 1,4-dihydropyridine derivative) and mildronate (a representative of the aza-butyrobetaine class) possessed considerable anti-inflammatory and neuroprotective properties in different in vitro and in vivo model systems. The present study investigated their stroke-protecting ability in an endothelin-1 (ET…

MaleDihydropyridinesDrug Evaluation PreclinicalInfarctionBrain damagePharmacologyNeuroprotectionIn vivomedicineAnimalsRats WistarStrokeEndothelin-1business.industryGeneral Medicinemedicine.diseaseRatsStrokeDisease Models AnimalNeuroprotective AgentsMechanism of actionendothelin-1; ischemic stroke; neurodegeneration; protection; cerebrocrast; mildronateDrug Therapy Combinationmedicine.symptombusinessReperfusion injuryEx vivoMethylhydrazinesMedicina; Volume 48; Issue 10; Pages: 77
researchProduct

Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease

2010

Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) that was generated via a unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6‑OHDA). We assessed the expression of cell biomarkers that are involved in signaling cascades and provide neural and glial integration: the neuronal marker TH (tyrosine hydroxylase); …

MaleNitric Oxide Synthase Type IIlcsh:ChemistryUbiquitinNeurotoxinlcsh:QH301-705.5Receptor Notch3SpectroscopyNeuronsReceptors NotchbiologyGlial fibrillary acidic proteinMicrofilament ProteinsGeneral MedicineComputer Science ApplicationsCell biologySubstantia NigraNitric oxide synthaseNeuroprotective Agentsmedicine.anatomical_structureBiochemistryNeurogliaNeurogliaMethylhydrazinesneuroimmunological biomarkersTyrosine 3-Monooxygenasesmall moleculeSubstantia nigraParkinson’s disease; 6-OHDA model; neuroimmunological biomarkers; mildronate; small moleculeNeuroprotectionArticleCatalysisInorganic ChemistryGlial Fibrillary Acidic ProteinmedicineAnimalsParkinson Disease SecondaryRats WistarPhysical and Theoretical ChemistryOxidopamineMolecular BiologyTyrosine hydroxylase6-OHDA modelCalcium-Binding ProteinsmildronateOrganic ChemistryCorpus StriatumRatslcsh:Biology (General)lcsh:QD1-999nervous systemParkinson’s diseasebiology.proteinBiomarkersInternational Journal of Molecular Sciences
researchProduct

Mildronate as a Regulator of Protein Expression in a Rat Model of Parkinson’s Disease

2011

Background. Mildronate (3-[2,2,2-trimethylhydrazinium] propionate dihydrate) traditionally is a well-known cardioprotective drug. However, our recent studies convincingly demonstrated its neuroprotective properties. The aim of the present study was to evaluate the influence of mildronate on the expression of proteins that are involved in the differentiation and survival of the nigrostriatal dopaminergic neurons in the rat model of Parkinson’s disease (PD). The following biomarkers were used: heat shock protein 70 (Hsp70, a molecular chaperone), glial cell line-derived nerve growth factor (GDNF, a growth factor promoting neuronal differentiation, regeneration, and survival), and neural cell …

biologybusiness.industryGrowth factormedicine.medical_treatmentSubstantia nigraGeneral MedicineStriatumPharmacologyNeuroprotectionHsp70Nerve growth factornervous systemmedicineGlial cell line-derived neurotrophic factorbiology.proteinmildronate; protein expression; neuroprotectionNeural cell adhesion moleculebusinessMedicina
researchProduct

L-karnitīna biosintēzes inhibitora mildronāta neirotropo efektu pētījumi eksperimentālajos modeļos

2014

Elektroniskā versija nesatur pielikumus

cerebrālā išēmijaL-karnitīnsmildronatePharmaceutical pharmacologysexual behaviourseksuālā uzvedībamitohondriju funkcijastrokemitochondrial functionmildronātsFarmaceitiskā farmakoloģijaL-carnitineMedicineMedicīna un farmācijaVeselības aprūpeMedicīna
researchProduct

A Dose-Dependent Improvement in Exercise Tolerance in Patients With Stable Angina Treated With Mildronate: A Clinical Trial “MILSS I”

2011

Objective. To assess the efficacy of various doses of Mildronate in combination with standard therapy for the exercise tolerance of patients with stable angina pectoris. The primary efficacy variable was the change in exercise time in bicycle ergometry from the baseline to 12 weeks of treatment. The secondary endpoints were the changes in maximum achieved load and time to the onset of angina from the baseline to week 12. Material and Methods. A total of 512 patients with chronic coronary heart disease who had ischemia as the limiting factor in the exercise test from 72 study centers in 4 countries were enrolled in this prospective, randomized, double-blind, placebo controlled phase 2 study.…

medicine.medical_specialtybusiness.industryIschemiaPhases of clinical researchGeneral Medicinemedicine.diseasePlaceboEffective dose (pharmacology)law.inventionSurgeryAnginaClinical trialDose–response relationshipmildronate; partial fatty acid oxidation inhibition; exercise tolerance; stable anginaRandomized controlled triallawAnesthesiamedicinebusinessMedicina; Volume 47; Issue 10; Pages: 78
researchProduct